ClinicalTrials.gg
TerminatedNCT02922413Updated Jan 30, 2026Results posted

Panhematin for Prevention of Acute Attacks of Porphyria

A Phase 2 interventional study of Hemin for injection and Placebo in Acute Intermittent Porphyria, Hereditary Coproporphyria and Variegate Porphyria, sponsored by The University of Texas Medical Branch, Galveston. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by The University of Texas Medical Branch, Galveston · Phase 2, Interventional, and Prevention

How we know

Why this study was terminated
Low accrual

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Porphyria, Acute Intermittent with a site in United States — 2 open to participants now, 3 under way, none of them phase 3. Porphyria, Acute Intermittent · United States.

Started
2015
with 1 other
Phase 2
2 of 12
none open now
Registered
6th of 12
by date
Lead sponsor
3 of 12
The University of Texas Medical Branch, Galveston

Among the 12 studies in Porphyria, Acute Intermittent with a site in United States, this one is one of 2 that started in 2015, is one of 2 in phase 2, and was the 6th registered.

Porphyria, Acute Intermittent

21 studies on the registry are indexed under Porphyria, Acute Intermittent; 3 are open to participants now.

Browse Porphyria, Acute Intermittent studies →

Open to participants now

2 of the 12 studies in Porphyria, Acute Intermittent with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Porphyria, Acute Intermittent studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Porphyria, Acute Intermittent with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine if Panhematin is safe and effective for prevention of acute attacks of porphyria.

The study aims to provide high quality evidence for the use on hemin for prevention of acute attacks of porphyria. High quality studies have not been done previously for treating or preventing acute attacks with hemin. The lack of strong evidence for efficacy of hemin for treatment and prevention of attacks limits its availability for patients with acute porphyrias. Funding source: FDA Office of Orphan Product Development (FDA OOPD) FD-R-03720

Read the detailed description

This is a double-blind, randomized, placebo-controlled, parallel group trial investigating the efficacy and safety of Panhematin™ for preventing acute attacks in at least 20 subjects with well-documented acute porphyria (acute intermittent porphyria, hereditary coproporphyria or variegate porphyria). Subjects will (1.) have had frequent attacks in the past, with symptoms such as abdominal, back and/or limb pain and diagnosed after exclusion of other causes, and (2.) be on hemin prophylaxis for prevention of frequent attacks. It is expected that they will have had 6 or more attacks in one year before starting hemin prophylaxis. This would be considered justification for a preventive regimen of hemin on clinical grounds. Double blind Panhematin™ or placebo will be given. The number of doses will correspond to the number of doses that a subject receives in approximately one week for their prophylactic regimen. An interim analysis will be carried out after completion of 10 subjects to assess progress and possibly adjust the sample size. The trial consists of the following visits:

  • A screening visit to determine eligibility and obtain informed consent.
  • A treatment visit for administration of double blind prophylactic doses of Panhematin™ or placebo corresponding to the number of doses the subject receives for their prophylactic regimen within approximately one week.
  • Follow up visit at 1, 2, 3, and 4 weeks to assess response to the infusion of Panhematin™ or placebo. These visits will be in person or by telephone.
  • Additional visits may be scheduled if needed, for example for treatment of symptoms.
  • Follow-up visits 3 and 6 months after the end of treatment either in person or by telephone Subjects will have laboratory documentation of one of the acute porphyrias. Molecular documentation is also expected, although rarely a causative mutation cannot be detected. Upon entry into the study they will be given in a blinded fashion one or more preventive doses of either Panhematin™ (4 mg/kg) or placebo, the number of which will correspond to the number of prophylactic doses they have been receiving within approximately one week for prophylaxis. A recurrent attack within the next 1, 2, 3 and 4 weeks will represent treatment failures. Because at study entry most subjects are expected to be on weekly prophylactic hemin treatment, and hemin is a short-acting drug, emphasis in the analysis will be on attacks occurring within 1 week after study treatment.

Any attacks that occur during the study will be treated according to standard of care, which may include Panhematin™, either at the study site or at a subject's usual treatment location.

It is intended that 20 subjects will complete treatment with blinded treatment and at least 4 weeks of follow up. A completed subject is one who meets all entrance criteria, has no exclusion criteria and completes the single dosing and at least one week of follow up, or is withdrawn because of an adverse event.

03

Conditions studied

  • Acute Intermittent Porphyria
  • Hereditary Coproporphyria
  • Variegate Porphyria

Keywords

  • Porphyria
  • Heme
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged 18 years
  2. Willing to provide written
  3. A diagnosis of acute intermittent porphyria, hereditary coproporphyria or variegate porphyria confirmed by the following criteria, which are based on the criteria for enrollment in the Longitudinal Study of the Porphyrias Consortium. For each type of porphyria, the inclusion criteria are based on 1) clinical features, 2) biochemical findings, as documented by laboratory reports (or copies) of porphyria-specific testing, and 3) molecular studies to identify a mutation in a porphyria-related gene. Equivocal biochemical measurements may require confirmatory testing. Testing for a disease-causing mutation must be attempted, but an identified mutation is not essential for enrollment, since it is known that a mutation cannot be found in a small fraction (\<5%) of biochemically proven cases of porphyria. Subjects will (1.) have had frequent attacks in the past, with symptoms such as abdominal, back and/or limb pain and diagnosed after exclusion of other causes, and (2.) be on hemin prophylaxis for prevention of frequent attacks. It is expected that they will have had 6 or more attacks in one year before starting hemin prophylaxis.

Exclusion criteria

Exclusion Criteria:

  1. Symptoms such as abdominal, back or limb pain are explained by another condition, as judged by the investigator
  2. Known or suspected allergy to Panhematin™ or related products
  3. A known or suspected allergy to human albumin
  4. Any disease or condition that the investigator judges would lead to an unacceptable risk to the patient or interfere with the successful collection of data for the trial
  5. Previous randomization in this trial
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Hemin for injection

    Double blind doses of Panhematin 4 mg/kg body weight reconstituted with 25% human albumin and infused over at least one hour.

    Biological: Hemin for injection

  • Placebo comparator
    Placebo

    A double blind dose of saline.

    Other: Placebo

Interventions

  • BiologicalHeminStudies of HeminHemin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Panhematin 4 mg/kg body weight reconstituted with 25% human albumin infused intravenously over at least 1 hour.

    Also known as: Hematin

  • OtherPlacebo

    Saline infusion

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Acute Attacks of Porphyria After Treatment

    Participants were interviewed weekly by telephone to record the number of acute porphyria attacks after initial treatment with Panhematin or placebo.

    Time frame: 1-4 weeks

  2. Number of Participants With Treatment-Related Serious Adverse Events

    The number of participants who experience treatment-related serious adverse events (SAEs) as assessed and graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

    Time frame: 1-4 weeks

Other outcomes

  1. Effects on Levels of Porphobilinogen

    To evaluate the biochemical effects of Panhematin™ in patients treated with Panhematin™ to prevent attacks of acute porphyria by measuring urinary porphobilinogen and serum porphobilinogen. This will determine whether biochemical measurements are predictive of efficacy in preventing an attack.

    Time frame: 1-4 weeks

  2. Effects of Age

    To evaluate effects of age, as an example of clinical features, on response to preventive administration of Panhematin™.

    Time frame: 1-4 weeks

  3. Effects of the Nature of the Porphobilinogen Deaminase (PBGD) Mutation

    To evaluate effects of the nature or the PBGD mutation on response to preventive Panhematin™

    Time frame: 1-4 weeks

  4. Frequency of Injection Site Complications

    To evaluate the use of Panhematin™ reconstituted with 25% human albumin in patients treated to prevent acute attacks of porphyria in terms of the frequency of injection site complications, which may include thrombosis or inflammation.

    Time frame: 1-4 weeks

07

Results

Posted Jan 30, 2026

Participant flow

Participant flow — Overall Study
MilestoneHemin for InjectionPlacebo
Started76
Completed76
Not completed00

Outcome measures

PrimaryNumber of Participants Experiencing Acute Attacks of Porphyria After Treatment

Participants were interviewed weekly by telephone to record the number of acute porphyria attacks after initial treatment with Panhematin or placebo.

Time frame:
1-4 weeks
Reported as:
Count of participants · Participants
Number of Participants Experiencing Acute Attacks of Porphyria After Treatment
ParticipantsHemin for InjectionPlacebo
Number of Participants Experiencing Acute Attacks of Porphyria After Treatment15
Statistical analysis
  • Hemin for Injection vs Placebo · 2-sided Fisher's Exact Test · p = 0.029
PrimaryNumber of Participants With Treatment-Related Serious Adverse Events

The number of participants who experience treatment-related serious adverse events (SAEs) as assessed and graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

Time frame:
1-4 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Related Serious Adverse Events
ParticipantsHemin for InjectionPlacebo
Number of Participants With Treatment-Related Serious Adverse Events00
Other pre-specifiedEffects on Levels of Porphobilinogen

To evaluate the biochemical effects of Panhematin™ in patients treated with Panhematin™ to prevent attacks of acute porphyria by measuring urinary porphobilinogen and serum porphobilinogen. This will determine whether biochemical measurements are predictive of efficacy in preventing an attack.

Time frame:
1-4 weeks

Results for this outcome have not been posted.

Other pre-specifiedEffects of Age

To evaluate effects of age, as an example of clinical features, on response to preventive administration of Panhematin™.

Time frame:
1-4 weeks

Results for this outcome have not been posted.

Other pre-specifiedEffects of the Nature of the Porphobilinogen Deaminase (PBGD) Mutation

To evaluate effects of the nature or the PBGD mutation on response to preventive Panhematin™

Time frame:
1-4 weeks

Results for this outcome have not been posted.

Other pre-specifiedFrequency of Injection Site Complications

To evaluate the use of Panhematin™ reconstituted with 25% human albumin in patients treated to prevent acute attacks of porphyria in terms of the frequency of injection site complications, which may include thrombosis or inflammation.

Time frame:
1-4 weeks

Results for this outcome have not been posted.

Adverse events

Collected over 1-4 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Hemin for Injection0/7 (0%)0/7 (0%)0/7 (0%)
Placebo0/6 (0%)0/6 (0%)0/6 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Hemin for InjectionPlaceboTotal
<=18 years000
Between 18 and 65 years7613
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Hemin for InjectionPlaceboTotal
Female6612
Male101
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Hemin for InjectionPlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino7613
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Hemin for InjectionPlaceboTotal
United States7613
08

Study locations

1 site
  • University of Texas Medical Branch
    Galveston, Texas 77555, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2015 to primary completion in Dec 2023, 97 months.

Results were first posted in Jan 2026, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 1, 2016
First posted
Oct 4, 2016
StartActual
Oct 30, 2015
Primary completionActual
Dec 27, 2023
CompletionActual
Dec 27, 2023
Results first posted
Jan 30, 2026
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02922413
Responsible party
Sponsor
First posted
Oct 4, 2016
Start date
Oct 30, 2015
Primary completion
Dec 27, 2023
Completion
Dec 27, 2023
Results posted
Jan 30, 2026
Last update
Jan 30, 2026

Study contacts

Karl E Anderson, MD
principal investigator · University of Texas

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hemin

Start the discussion